Boston Scientific showcases over 80 innovative products at 8th CIIE, embodying "global innovation + local manufacturing"

Boston Scientific was founded in the United States in 1979 and is one of the medical device companies with the largest R&D investment globally. Since its establishment, it has been committed to leading the development of minimally invasive interventional technologies. Ten of its products or technologies have been nominated for or won the prestigious "Prix Galien" award in the medical field.

Under the theme "Advancing Science for Life, Moving Ahead Together," Boston Scientific brought over 80 innovative products covering cardiac, peripheral vascular, oncology, urology, digestive, and neuromodulation areas, with six products making their debut,fully showcasing the company's robust innovation momentum driven by the dual engines of "global innovation + local manufacturing."

As a medical technology company with the mission of "innovating for life," Boston Scientific participates in the exhibition every year, committed to bringing more innovative achievements that meet local clinical needs to the CIIE stage, hoping to benefit a wide range of Chinese patients with its continuously innovative core strength. At this year's CIIE, Boston Scientific has six products making their "first appearance."

1. Boosting the "Silver Economy"

(1) FARAWAVE NAV Single-Use Magnetic Navigation Cardiac Pulse Field Ablation (PFA) Catheter*：The newly added magnetic positioning function enables complementary use to help accurately reconstruct the cardiac anatomy, optimize the workflow for atrial fibrillation ablation procedures, and deliver a superior diagnosis and treatment experience for both physicians and patients.

(2) AdVance XPUrethral Sling*：The world's first male stress urinary incontinence sling, specifically addressing the often-unspoken challenge of stress urinary incontinence in elderly men.

(3) ENROUTE Transcarotid Retrograde Flow Thromboprotection Device: The world's first and only reverse-flow thrombus protection device approved for TransCarotid Artery Revascularization (TCAR) procedures, offering a broader range of treatment options for patients with carotid artery stenosis.

(4) TIVUS Renal Artery Ultrasound Ablation Catheter*：It is a consumable of the TIVUS intravascular ultrasound system, which can reduce renal nerve activity through renal artery denervation (RDN) as an alternative or adjunct therapy to antihypertensive drugs, helping Hypertension The patient regulates blood pressure.

2. Healthy Weight Management

The Orbera365 Intragastric Balloon System*：A representative weight loss product responding to the "Year of Weight Management" initiative, filling technological gaps in the field of endoscopic weight loss in China.

3. Major Disease Tumor Treatment

Intera 3000 Hepatic Artery Infusion Pump*：The only FDA-approved Hepatic Artery Infusion (HAI) therapy product in the United States for patients with colorectal cancer liver metastases and intrahepatic cholangiocarcinoma.

1. "Exhibits Turn into Goods"Results

Since participating in the exhibition, Boston Scientific has successfully brought 22 exhibited products to the Chinese market leveraging the CIIE effect, achieving the transformation of "exhibits into commodities." These products demonstrate Boston Scientific's technological leadership, innovation, and clinical application value across various disease areas, and will all be showcased at this year's CIIE booth, highlighting Boston Scientific's commitment to empowering the "Healthy China" initiative with innovative medical technologies and cutting-edge medical concepts. Meanwhile, several pre-market exhibits have also leveraged innovative access pathways to pioneer clinical applications in China.

(1) Hainan Lecheng Pilot Zone:

When Boston Scientific made its debut at the CIIE in 2019, it "formed a connection" with the Lecheng Pilot Zone, becoming one of the first strategic partners of the Lecheng Pilot Zone. Currently, Boston Scientific has 15 products in the "pilot-first" program there.

For inoperable liver cancer, Y-90 glass microspheres* are a treatment method that combines the dual advantages of precise minimally invasive intervention and accurate nuclear medicine diagnosis and therapy. In May 2024, Shanghai Ruijin Hospital Hainan Hospital conducted its first 'pioneering' clinical application of Y-90 glass microspheres. This marked the first Y-90 glass microsphere procedure in China to receive payment reimbursement through participation in inclusive commercial supplemental health insurance (commonly known as 'Huimin Insurance') since the precision therapy was included in such insurance schemes across various regions. Currently, three medical institutions in the Lecheng Pilot Zone have been approved to carry out this precision therapy, further supporting the goal of 'treating serious illnesses without going abroad.

(2) Guangdong-Hong Kong-Macao Greater Bay Area:

Leveraging the innovative policy of the "Hong Kong-Macao Medicine and Device Access Program," Boston Scientific has already introduced several innovative products for clinical use in the Greater Bay Area.

In 2023, the Orbera series for healthy weight management made its debut at the CIIE, immediately capturing cross-sector attention. In April of this year, the Orbera365 Intragastric Balloon System became one of the first single-balloon weight management products introduced under the "Greater Bay Area (GBA) Access Policy" for drugs and medical devices. Less than four months later, the first patient in China to receive the Orbera365 system was successfully discharged from Nanfang Hospital of Southern Medical University. This procedure enabled the Orbera series to benefit patients in the Greater Bay Area ahead of schedule. Within just three weeks post-procedure, this severely obese patient (with a BMI of 47) lost 35 jin (approximately 17.5 kg), with expectations for continued weight reduction. As the weight decreased, the patient's health condition and mental state improved significantly, laying a solid foundation for their return to the workplace.

2. Progress of "Exhibitors Turning into Investors"

(1) Local Production

Building on the spillover effects of the CIIE, Boston Scientific has continuously increased its local investment and research efforts under the innovation of national systems and the ongoing optimization of Shanghai's business environment, advancing its localization strategy and achieving a series of results.

● October 2024, Boston Scientific Shanghai Lingang Factory Officially completed and opened for business, this is Boston Scientific China's first production and manufacturing base. With the support of a package of preferential policies and well-established supporting facilities in the Lingang Special Area, government departments at all levels have played an active role in taking multiple measures to provide comprehensive guarantees for the factory construction.

● Since the Lingang plant became operational, type-testing samples of four innovative products have successfully rolled off the production line. These include the OptiCross/OptiCross HD Catheters** for use with the AVVIGO+ Intravascular Ultrasound (IVUS) Diagnostic System, the Rezūm EVO System* for treating male benign prostatic hyperplasia (BPH), and the next-generation FARASTAR* Magnetically Guided Multi-Channel Pulsed Field Ablation System for atrial fibrillation ablation. Clinical reports for all four products have been completed and submitted for registration.

● By 2026, the Lingang plant is expected to achieve local production of the aforementioned IVUS catheter consumables, further assisting Boston Scientific in establishing a more self-reliant and controllable localized production system.

(2) Ecosystem Cooperation

Leveraging the platform effect of the CIIE, Boston Scientific explores innovative cooperation models with more like-minded ecosystem partners, helping to upgrade and expand the value chain of China's medical industry.

● In September 2025, Boston Scientific partnered with Siemens Healthineers and Danaher to jointly create an "Advanced Medical Technology Collaboration Platform" that integrates medical skill enhancement, medical-engineering technology transformation, and intelligent medical applications. The three companies will leverage their comprehensive strengths in medical technology, clinical diagnosis and treatment, and scientific research innovation to promote collaborative research and the transformation of achievements into applications.

● During this year's CIIE, the three enterprises will jointly support the 2025 Global Medical Technology Innovation Ecosystem Conference, engaging with partners from industry, academia, research, medicine, and policy to discuss cutting-edge medical technologies and the advancement of China's industry, helping more original clinical innovations and medical engineering transformation results in China come to fruition.

AI technology serves as an "amplifier" to enhance the utilization efficiency of medical resources. It can refine clinicians' experience into more customized, data-driven decisions, helping to address the healthcare "impossible trinity" of affordability, accessibility, and quality of care. At this year's CIIE, Boston Scientific established its first dedicated AI application exhibition zone, showcasing multiple innovative achievements in this field.

(1) Representative of Boston Scientific's AI Technology Applications in China

The use of Intravascular Ultrasound (IVUS) in Percutaneous Coronary Intervention (PCI) significantly reduces the risk of major adverse events. In the long term, it also alleviates the economic burden on both hospitals and patients, demonstrating superior health economic benefits. The new-generation Intravascular Ultrasound diagnostic system AVVIGO+, which has attracted significant attention since its debut at the 2023 CIIE, is Boston Scientific's first AI-enabled system implemented in the IVUS field. It is also the first IVUS system with AI capabilities approved by the U.S. FDA, filling the gap in AI application for IVUS systems.

·Improving Diagnostic Accuracy and Surgical Efficiency

The AVVIGO+ system can automatically perform key operational steps and provide precise vascular measurement data. Compared to the previous generation of IVUS systems, using the AVVIGO+ system reduces operation time by 62%, saving an average of 15 to 20 minutes per procedure. This allows hospitals to conduct one additional surgery per day in each catheterization lab, enhancing the diagnostic service capacity and operational efficiency at grassroots-level healthcare facilities.

·Lower the Learning Threshold for Grassroots Doctors

The AI function of the AVVIGO+ system can help doctors assess the severity of internal blockages and stenosis in coronary arteries, providing decision-making support for precision treatment while shortening the learning curve for grassroots doctors' professional skills. Research shows that the diagnostic results provided by the machine have a consistency of over 99% compared to experts.

2. Boston Scientific's Other Explorations in AI Technology Applications

Through big data analysis + AI technology and the integration of real-world data, Boston Scientific has independently developed multiple AI technologies and algorithms to precisely match therapies for patients, offering more effective and stable solutions, reshaping the patient journey, and enhancing patient care.

(1) Early Warning for Proactive Disease Intervention
The HeartLogic Heart Failure Monitoring System is the first heart failure early warning system approved by the U.S. FDA. It tracks vascular system data and uses intelligent algorithms to generate an intuitive heart failure index, providing clinicians with 34 days of advance warning about changes in heart failure risk. This facilitates a shift in healthcare from passive, reactive treatment toward active, preventive intervention.

(2) Enhancing Diagnostic Accuracy and Efficiency with AI Algorithms
The BeatLogic Cardiac Algorithm* employs AI technology and deep learning models to automatically interpret massive volumes of ECG data. It can precisely identify different types of arrhythmic events, deliver more timely and accurate reporting notifications, assist clinicians in saving working time, optimize treatment plans, and ultimately improve patient outcomes.

China's elderly population has surpassed 300 million. As the degree of population aging deepens, China is at a critical window period for addressing the challenges of aging. To promote the prosperous development of the silver economy and establish the new concept of "positive aging and healthy aging," Boston Scientific has gained deep insights into local medical and patient needs. Focusing on diseases that are common and frequently occur among the elderly population, the company has brought a series of innovative products in the field of minimally invasive interventions to this year's CIIE.

1. Cardiovascular Health Field

(1) One-stop Solution for Atrial Fibrillation

As the first company in the world to offer a portfolio of innovative AFib solutions comprising both left atrial appendage closure devices and pulsed field ablation systems, Boston Scientific has been piloting integrated one-stop AFib procedures for patients at high stroke risk, performing left atrial appendage occlusion during AFib ablation. This year, the next-generation WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device received approval in China and will be showcased at the CIIE alongside the FARAPULSE™ Pulsed Field Ablation (PFA) System. The FARAPULSE™ System has already been used to treat 500,000 patients globally, further advancing clinical consensus for this innovative procedure that advocates an integrated prevention and treatment approach with comprehensive management.

(2) ICDTherapy

In 1985, Boston Scientific launched the first commercially available Implantable Cardioverter Defibrillator (ICD) approved by the U.S. FDA, ushering in a new era in the prevention and treatment of sudden cardiac death, and becoming the "pioneer" of ICD therapy. Over the past 40 years, Boston Scientific has continuously advanced ICD technology, driving its evolution towards being more lightweight, precise, and intelligent. At this year's CIIE, Boston Scientific will showcase its ICD products, including the world’s first approved Subcutaneous Implantable Cardioverter Defibrillator (S-ICD), as well as those approved domestically last year Cardiac Resynchronization Therapy Defibrillator (CRT-D) Will be displayed together in the "combined" exhibition.

2. Men's Health Field

Focusing on the issue of frequent urination difficulties in elderly men, Boston Scientific's three "first-ever" urology products will make their debut together at the "Clover" venue: the world's first thermal vapor therapy system for treating benign prostatic hyperplasia. Rezūm Thermal vapor therapy equipment and disposable prostate thermal vapor therapy instruments, with an average operation time of only 5-8 minutes, can be completed under local anesthesia. In addition, the world's first male stress urinary incontinence sling AdVance XP*, and the first and only artificial urethral sphincter product in China AMS 800Urinary Control System, which will bring good news to the vast number of male patients with stress urinary incontinence.

3. Neuromodulation Field

Parkinson's disease is a common neurodegenerative disorder in middle-aged and elderly people. Currently, there is no cure, but medications can control symptoms, although some have side effects, and their efficacy may diminish as the disease progresses. Implantable deep brain stimulation (DBS) therapy has become an effective surgical treatment due to its minimally invasive, reversible, and adjustable advantages. Boston Scientific's Vercise Genus DBS System With technical features such as precision, visualization, and long service life, it can adjust treatment methods based on the patient's disease condition. Through more precise and personalized neurostimulation parameter settings, it achieves greater patient benefits. In April this year, this product completed its first round of clinical applications domestically.

* Product not yet available in mainland China

 ** The domestic version of the product has not yet been launched in China.

Boston Scientific is committed to innovation for life. We are dedicated to innovative medical solutions that improve the lives of patients around the world. For over 45 years, Boston Scientific has been at the forefront of the global medical technology industry, providing a wide range of high-performance medical solutions to meet the critical treatment needs of many patients and reduce healthcare costs. Boston Scientific's medical devices and related therapies assist doctors in diagnosing and treating complex diseases of the cardiovascular, respiratory, digestive, oncological, neurological, and urological systems.

Boston Scientific established its China headquarters in Shanghai in 1997, marking the start of its operations in China. The company currently has branches in Beijing, Guangzhou, Chengdu, Hong Kong, and Taipei. Its core business areas include cardiac intervention, cardiac rhythm management, atrial fibrillation solutions, peripheral intervention, oncology intervention, endoscopic intervention, urology, neuromodulation, and respiratory intervention. Upholding its tradition as an innovation leader, Boston Scientific is committed to becoming a medical technology company that meets the needs of doctors and patients and demonstrates innovative vitality by providing medical products and services for disease prevention, diagnosis, and treatment.